华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的临床观察
TITLE:
摘要: 目的:观察华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的疗效和安全性。方法:92例中晚期宫颈癌患者随机分为对照组(46例)和观察组(46例)。两组患者均采用盆腔调强适形放射治疗+近距离放射治疗。在此基础上,对照组患者给予紫杉醇注射液135 mg/m2,d1+顺铂注射液75 mg/m2,d1,21 d为1个周期,放疗第1天开始化疗,放疗期间同步化疗2个周期。观察组患者在对照组治疗的基础上给予华蟾素胶囊0.5 g,口服,每日3次,于放疗当天开始口服,直至放疗结束。观察两组患者的临床疗效,治疗前后血小板、功能状态(KPS)评分、体质量,疼痛患者的缓解情况及血小板异常患者的恢复情况,并记录毒性反应发生情况。结果:观察组患者完全缓解率、血小板异常患者的恢复正常率、疼痛患者治疗3周后的缓解率及总缓解率均显著高于对照组,差异均有统计学意义(P<0.05);两组患者总有效率及疼痛患者治疗4、5周后的缓解率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者血小板均显著低于同组治疗前,且观察组显著低于对照组;两组患者KPS评分及观察组患者的体质量均显著高于同组治疗前,对照组患者的体质量显著低于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者Ⅲ~Ⅳ级白细胞下降、恶心呕吐发生率,Ⅰ~Ⅱ级腹泻发生率均显著低于对照组,差异均有统计学意义(P<0.05)。结论:在常规治疗的基础上,华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的疗效显著,可改善患者血液高凝状态及生存质量,减轻疼痛,降低毒性反应的发生。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy and safety of cinobufacini capsules combined with paclitaxel and cisplatin in the treatment of middle and advanced cervical cancer. METHODS: A total of 92 patients with middle and advanced cervical cancer were randomly divided into observation group(46 cases) and control group(46 cases). Both groups received pelvic intensity-modulated radiotherapy (IMRT)+interstitial brachytherapy. Control group was additionally given Paclitaxel injection 135 mg/m2,d1+Cisplatin injection 75 mg/m2,d1,21 d as a treatment course, and received chemotherapy for 2 cycles since the first day of radiotherapy. Observation group was additionally given Cinobufacini capsules 0.5 g orally since the first day of radiotherapy, 3 times a day, until the end of radiotherapy. Clinical efficacies as well as platelet count, KPS score, body weight, pain relief and the recovery of platelet abnormality were observed in 2 groups, and the occurrence of toxic reaction was recorded. RESULTS: The complete remission rate, the rate of platelet count abnormality recovery as well as remission rate and total remission rate of pain after 3 weeks of treatment in observation group were significantly higher than control group, with statistical significance (P<0.05). There was no statistical significance in the total response rate and remission rate after 4, 5 weeks of treatment between 2 groups (P>0.05). After treatment, platelet count of 2 groups were significantly lower than before, and the observation group was significantly lower than the control group; KPS score of 2 groups and body weight of observation group were significantly higher than before treatment; body weight of control group was significantly lower than before, and the observation group was significantly higher than the control group, with statistical significance (P<0.05). The incidence of grade Ⅲ-Ⅳ neutropenia, nausea and vomiting, grade Ⅰ-Ⅱ diarrhea in observation group were significantly lower than control group, with statistical significance (P<0.05). CONCLUSIONS: Based on conventional treatment, cinobufacini capsules combined with paclitaxel and cisplatin show significantly therapeutic efficacy for middle and advanced cervical cancer, improve blood hypercoagulation and survival quality, relieve pain and reduce the occurrence of toxic reaction.    
期刊: 2017年第28卷第24期
作者: 佐志刚,汤继英,蔡晓军
AUTHORS: ZUO Zhigang,TANG Jiying,CAI Xiaojun
关键字: 宫颈癌;同步放化疗;华蟾素胶囊;紫杉醇;顺铂;疗效;安全性
KEYWORDS: Cervical cancer; Concurrent chemoradiotherapy; Cinobufacini capsule; Paclitaxel; Cisplatin; Therapeutic efficacy; Safety
总下载数: 4 次
本日下载数: 0次
本月下载数: 0次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!